Morgan Stanley
LXEO icon

Morgan Stanley’s Lexeo Therapeutics LXEO Stock Holding History

Morgan Stanley’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Sell
395,102
-7,822
-2% -$42.3K ﹤0.01% 4897
2026
Q1 		$2.31M Buy
402,924
+262,743
+187% +$1.86M ﹤0.01% 4663
2025
Q4 		$1.39M Buy
140,181
+42,124
+43% +$384K ﹤0.01% 5015
2025
Q3 		$651K Buy
98,057
+13,276
+16% +$64.2K ﹤0.01% 5396
2025
Q2 		$341K Buy
84,781
+465
+0.6% +$1.53K ﹤0.01% 5636
2025
Q1 		$293K Buy
84,316
+9,488
+13% +$42K ﹤0.01% 5575
2024
Q4 		$492K Sell
74,828
-167,000
-69% -$1.32M ﹤0.01% 5422
2024
Q3 		$2.19M Buy
241,828
+229,165
+1,810% +$2.73M ﹤0.01% 4586
2024
Q2 		$203K Sell
12,663
-1,281
-9% -$18.6K ﹤0.01% 5668
2024
Q1 		$219K Buy
13,944
+4,456
+47% +$69.7K ﹤0.01% 5705
2023
Q4 		$127K Buy
+9,488
New +$118K ﹤0.01% 5856

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Morgan Stanley's LXEO Position: Q2 2026 in Review

Morgan Stanley reduced its Lexeo Therapeutics (LXEO) stake by 1.9% in Q2 2026, selling an estimated $42.3K and leaving 395,102 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #4897.

Morgan Stanley first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.31M in Q1 2026. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Morgan Stanley held 395,102 shares of Lexeo Therapeutics worth $1.84M as of Q2 2026.
  • Morgan Stanley sold 7,822 Lexeo Therapeutics shares in Q2 2026, an estimated $42.3K.
  • Lexeo Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4897 holding.
  • Morgan Stanley first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Morgan Stanley's Lexeo Therapeutics position peaked at $2.31M in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.